Program Overview (5 mins)
Key Studies Influencing My Practice Following AASLD 2022 (25 mins)
- Summary of the most important HBV, HCV, and HDV studies
- Key clinical practice recommendations
Question and Answer Session (15 mins)
Date / Time
Nancy Reau, MD
Professor of Medicine
Chief, Section of Hepatology
Associate Director, Solid Organ Transplantation
Richard B. Capps Chair of Hepatology
Rush University Medical Center
Stefan Zeuzem, MD
Professor of Medicine
Chief, Department of Medicine
JW Goethe University Hospital
The goal of this activity is to improve learners’ competence in translating the most clinically important data from AASLD 2022 into practical management strategies for patients with or at risk of viral hepatitis.
This program is intended for physicians, pharmacists, and other healthcare professionals who care for patients with liver diseases.
Upon completion of this activity, participants should be able to:
- Integrate the results of recent clinical studies of HBV and HDV management strategies into clinical practice
- Evaluate the impact of results of clinical studies of investigational treatments for chronic HBV and HDV infection on current and future patient management strategies
- Implement new data on strategies for optimizing HCV care, including simplified approaches to HCV management
Joint Accreditation Statement
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Physician Continuing Medical Education
Designation of Credit
CCO designates this live activity for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Continuing Pharmacy Education
CCO designates this continuing education activity for .75 contact hours (0.075 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-22-272-L01-P
Type of Activity: Knowledge
Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.
Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.